[go: up one dir, main page]

AR102869A1 - Composiciones de insulina de rápida acción - Google Patents

Composiciones de insulina de rápida acción

Info

Publication number
AR102869A1
AR102869A1 ARP150103921A ARP150103921A AR102869A1 AR 102869 A1 AR102869 A1 AR 102869A1 AR P150103921 A ARP150103921 A AR P150103921A AR P150103921 A ARP150103921 A AR P150103921A AR 102869 A1 AR102869 A1 AR 102869A1
Authority
AR
Argentina
Prior art keywords
quick action
insulin compositions
action insulin
manufacture
chloride
Prior art date
Application number
ARP150103921A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55066806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR102869(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR102869A1 publication Critical patent/AR102869A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición de insulina humana o análogo de insulina que incluye concentraciones específicas de citrato, cloruro, en algunos casos que incluye la adición de cloruro de sodio, zinc y, opcionalmente, cloruro de magnesio y/o tensoactivo. Reivindicación 36: Uso de la composición farmacéutica de conformidad con cualquiera de las reivindicaciones 1 - 27, en la manufactura de un medicamento para el tratamiento de diabetes. Reivindicación 37: Un artículo de manufactura, caracterizado porque comprende cualquiera de las composiciones farmacéuticas de conformidad con las reivindicaciones 1 - 27.
ARP150103921A 2014-12-16 2015-12-01 Composiciones de insulina de rápida acción AR102869A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462092407P 2014-12-16 2014-12-16

Publications (1)

Publication Number Publication Date
AR102869A1 true AR102869A1 (es) 2017-03-29

Family

ID=55066806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103921A AR102869A1 (es) 2014-12-16 2015-12-01 Composiciones de insulina de rápida acción

Country Status (18)

Country Link
US (4) US9993555B2 (es)
EP (2) EP3233108B1 (es)
JP (5) JP6328855B2 (es)
AR (1) AR102869A1 (es)
CY (1) CY1125275T1 (es)
DK (1) DK3233108T3 (es)
ES (1) ES2911207T3 (es)
HR (1) HRP20220692T1 (es)
HU (1) HUE058764T2 (es)
LT (1) LT3233108T (es)
MA (1) MA41188B1 (es)
MD (1) MD3233108T2 (es)
PL (1) PL3233108T3 (es)
PT (1) PT3233108T (es)
RS (1) RS63174B1 (es)
SI (1) SI3233108T1 (es)
TW (1) TW201630622A (es)
WO (1) WO2016100042A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2254906T (pt) 2008-03-18 2017-01-03 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
WO2014076423A1 (fr) 2012-11-13 2014-05-22 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3518893A1 (en) * 2016-09-29 2019-08-07 Arecor Limited Novel formulations
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
WO2018153506A1 (en) * 2017-02-22 2018-08-30 Adocia Fast-acting insulin composition comprising a citric acid salt
MX2019011603A (es) * 2017-03-26 2021-08-16 Robyn Vivi Stafford Metodo de tratamiento de las condiciones de la piel de los parpados.
MX2019014195A (es) * 2017-06-01 2020-01-27 Lilly Co Eli Composiciones de insulina de rapida accion.
WO2019193351A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
US20210093775A1 (en) * 2018-04-04 2021-04-01 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
US12357562B2 (en) 2018-04-04 2025-07-15 Arecor Limited Injection pen system for the delivery of an insulin compound
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
EP4595775A3 (en) * 2019-03-14 2025-10-22 The Regents of the University of California Bhb-citrate combination products for renal health and treating disease
US10639328B1 (en) * 2019-03-27 2020-05-05 College Of William & Mary Compositions and methods for reducing hyperglycemia and treating diabetes
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
KR20220066317A (ko) * 2019-09-17 2022-05-24 카스 파마슈티컬스, 인크. 피하 주사가능 인슐린 제제 및 투여 방법
WO2021081404A1 (en) 2019-10-25 2021-04-29 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
JP7803868B2 (ja) * 2020-03-02 2026-01-21 サーマリン インク． 速効型インスリンアナログを含む組成物
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116527B (da) 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
EP0018609B1 (de) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
FI884914A0 (fi) 1987-02-25 1988-10-24 Novo Industri As Nya insulinderivat.
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
ES2180511T3 (es) 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
WO2001035943A2 (en) 1999-11-15 2001-05-25 Gangal Hanamaraddi T Dextrose and insulin fluid formulation for intravenous infusion
JP4147234B2 (ja) 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2005046716A1 (en) 2003-11-13 2005-05-26 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
ES2328048T3 (es) 2004-03-12 2009-11-06 Biodel, Inc. Composiciones de insulina con absorcion mejorada.
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008013955A2 (en) 2006-07-27 2008-01-31 Nektar Therapeutics Sustained release formulations for pulmonary delivery
ES2744384T3 (es) * 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
RU2533217C3 (ru) 2009-06-26 2020-12-21 Ново Нордиск А/С Препарат, содержащий инсулин, никотинамид и аминокислоту
WO2012006283A1 (en) 2010-07-07 2012-01-12 Biodel Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
CN103889443A (zh) 2011-06-17 2014-06-25 哈洛齐梅公司 使用透明质酸降解酶的持续皮下胰岛素输注法
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
CN105797140B (zh) 2011-06-17 2020-08-11 哈洛齐梅公司 乙酰透明质酸降解酶的稳定制剂
US20130231281A1 (en) * 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
JP6067746B2 (ja) 2011-12-30 2017-01-25 ハロザイム インコーポレイテッド Ｐｈ２０ポリペプチド変異体、その製剤および使用
US9399065B2 (en) * 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
WO2014076423A1 (fr) * 2012-11-13 2014-05-22 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
JP6944780B2 (ja) 2014-01-13 2021-10-06 サーマリン インコーポレイテッド 速効型インスリン製剤及び医薬送達システム
WO2015120457A1 (en) 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول

Also Published As

Publication number Publication date
US11872266B2 (en) 2024-01-16
JP2023011641A (ja) 2023-01-24
MD3233108T2 (ro) 2022-09-30
JP2021073187A (ja) 2021-05-13
JP2018138578A (ja) 2018-09-06
ES2911207T3 (es) 2022-05-18
EP3233108A1 (en) 2017-10-25
US11123406B2 (en) 2021-09-21
CY1125275T1 (el) 2024-12-13
TW201630622A (zh) 2016-09-01
EP4108253A1 (en) 2022-12-28
US20240238382A1 (en) 2024-07-18
JP2018500314A (ja) 2018-01-11
JP2025032126A (ja) 2025-03-11
JP7093669B2 (ja) 2022-06-30
EP3233108B1 (en) 2022-03-30
DK3233108T3 (da) 2022-04-11
US20190231851A1 (en) 2019-08-01
US9993555B2 (en) 2018-06-12
HUE058764T2 (hu) 2022-09-28
MA41188A (fr) 2017-10-24
PT3233108T (pt) 2022-05-05
PL3233108T3 (pl) 2022-06-20
US20220072105A1 (en) 2022-03-10
US20160166695A1 (en) 2016-06-16
SI3233108T1 (sl) 2022-05-31
LT3233108T (lt) 2022-05-10
HRP20220692T1 (hr) 2022-07-08
MA41188B1 (fr) 2022-08-31
RS63174B1 (sr) 2022-05-31
JP6328855B2 (ja) 2018-05-23
WO2016100042A1 (en) 2016-06-23
JP7159277B2 (ja) 2022-10-24

Similar Documents

Publication Publication Date Title
AR102869A1 (es) Composiciones de insulina de rápida acción
PE20180523A1 (es) Compuestos co-agonistas del glucacon y peptido-1 similar al glugacon (glp-1)
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
PE20161408A1 (es) Composiciones de insulina de rapida accion
PE20150092A1 (es) Composiciones farmaceuticas que contienen fumarato de dimetilo
CO2017008148A2 (es) Formulación en polvo nasal para el tratamiento de hipoglicemia
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2016002971A1 (es) Combinación.
MX2018002482A (es) Composiciones de insulina de rapida accion.
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
MX2015010139A (es) Composicion antiseptica oral para tratamiento de mucositis oral.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
AR106313A1 (es) Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
DOP2016000096A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
EP3533450C0 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ISCHEMIA-REPERFUSION INJURY, CONTAINING BILE ACID

Legal Events

Date Code Title Description
FB Suspension of granting procedure